hVIVO plc Directorate Change (8953U)
October 30 2017 - 3:00AM
UK Regulatory
TIDMHVO
RNS Number : 8953U
hVIVO plc
30 October 2017
For immediate release 7.00am: 30 October 2017
HVIVO PLC
("hVIVO" or the "Company")
Directorate Change
Trevor Phillips to assume role of Executive Chairman
Experienced biopharmaceutical executive will work closely with
existing management team to refine and focus strategy to drive the
business forward
hVIVO plc (AIM: HVO), a specialty biopharma company with
discovery and clinical development capabilities, today announces
the appointment of Dr Trevor Phillips as Executive Chairman,
succeeding current Non-Executive Chairman, Jaime Ellertson who has
held that position since June 2014. Jaime will remain on the board
as a Non-Executive Director. Based in the US, Jaime is currently
also CEO and Chairman of Everbridge Inc. (NASDAQ:EVBG).
Trevor will work closely with Kym Denny, CEO of hVIVO, to refine
and focus the Company's strategy to drive the business forward. He
has over thirty years' of experience in the pharmaceutical industry
and has a proven track record in corporate development. He was
previously Chief Operations Officer and President of US Operations,
as well as a member of the Board, at Vectura Group plc. Prior to
this, he served as Chief Executive Officer and Chief Operating
Officer at Critical Therapeutics Inc. and has also held senior
management positions at Sepracor, Inc. (now Sunovion
Pharmaceuticals, Inc.).
Trevor was originally appointed a Non-Executive Director of
hVIVO in June 2017 and will assume his new role on 13 November
2017.
Kym Denny, CEO of hVIVO, said:
"I am delighted that Trevor has accepted the role of Executive
Chairman and I, as well as the rest of the management team, look
forward to working closely with him. He has a wealth of experience
in the sector, serving in a number of senior management roles at
biopharmaceutical companies, including Vectura Group Plc, a company
that is also focused on diseases that impact the airways and that
has grown over time to become a constituent member of the FTSE 250.
Trevor's expertise in operations and corporate development in the
space will be invaluable as we seek to refine our strategy to drive
revenue growth and build a robust and profitable business that is
centred on our proprietary Pathomics platform.
I would like to thank Jaime for all his support and guidance as
Non-Executive Chairman over the past three years. This has been a
formative time for hVIVO as we have sought to strengthen the
Company's position as a specialised centre of excellence for the
clinical research and development of new therapies for respiratory
and infectious diseases. We look forward to continuing to benefit
from Jaime's counsel as a Non-Executive Director."
Speaking on his appointment as Executive Chairman of hVIVO, Dr
Trevor Phillips commented:
"I am excited at this opportunity to work with the hVIVO team to
drive the business forward. I believe the Pathomics platform that
the company has developed, coupled with the Company's clinical
expertise and know-how is a valuable and unique asset for those
involved in the discovery and development of drugs for diseases
that impact the airways and so enable precision therapies. I look
forward to guiding the management team to ensure that the
commercial potential of the platform and the business is realised
so as to generate significant and sustainable shareholder
value."
For further information please contact:
+44 207 756
hVIVO plc 1300
Kym Denny (Chief Executive
Officer)
Graham Yeatman (Chief Financial
& Business Officer)
Media Enquiries
+1 919 710
Susan Flood 9658
+44 207 260
Numis Securities Limited 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Michael Burke
(Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster +44 203 727
Mitchell (UK) 1000
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with
discovery and clinical testing capabilities, is pioneering a
human-based analytical platform to accelerate drug discovery and
development in respiratory and infectious diseases. Leveraging
human disease models in flu, RSV and asthma exacerbation, the hVIVO
platform captures disease in motion, illuminating the entire
disease life cycle from healthy to sick and back to health. Based
in the UK, market leader hVIVO has conducted more than 50 clinical
studies, inoculated over 2500 volunteers and has three
first-in-class therapies currently in development with a growing
pre-clinical pipeline.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOADMMZGVNRGNZM
(END) Dow Jones Newswires
October 30, 2017 03:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2023 to Apr 2024